US · TFX · MEDICAL - INSTRUMENTS & SUPPLIES
Teleflex Incorporated (TFX) intrinsic value and stock valuation
$161.58as of 2026-11-21 · Mkt cap 6.06B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Teleflex Incorporated DCF and intrinsic value
InvestorsCraft values TFX with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from TFX’s statements →
Teleflex Incorporated Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Arrowhead Pharmaceuticals, Inc. (ARWR) $41.37
- Krystal Biotech, Inc. (KRYS) $308.89
- Alkermes plc (ALKS) $44.94
- Vaxcyte, Inc. (PCVX) $55.39
- TG Therapeutics, Inc. (TGTX) $63.34
- Bausch + Lomb Corporation (BLCO) $19.38
- PTC Therapeutics, Inc. (PTCT) $56.42
- Stevanato Group S.p.A. (STVN) $15.65
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.99B | $3.05B | $2.97B | $2.79B | $2.81B |
| Operating income | $255.8M | $151M | $506.3M | $499.7M | $628.1M |
| Net income | -$-905.64M | $69.7M | $356.3M | $363.1M | $485.4M |
| EPSd | -$-20.25M | $1.48M | $7.53M | $7.68M | $10.2M |
| Operating cash flow | $340.7M | $635.7M | $510.6M | $342.1M | $651.4M |
| Capital expenditure | -$-95.24M | -$-126.43M | -$-91.44M | -$-79.19M | -$-71.62M |
| Free cash flow | $245.4M | $509.3M | $419.2M | $263M | $579.8M |
| Total assets | $6.95B | $7.1B | $7.53B | $6.93B | $6.87B |
| Total debt | $2.73B | $1.76B | $1.93B | $1.83B | $1.97B |
| Net debt | $2.33B | $1.46B | $1.7B | $1.54B | $1.52B |
| Total equity | $3.12B | $4.28B | $4.44B | $4.02B | $3.75B |
| Cash and short-term investments | $393.3M | $306.2M | $222.9M | $292M | $445.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.99B | $3.05B | $2.97B | $2.79B | $2.81B |
| Cost of revenue | $872M | $1.34B | $1.33B | $1.26B | $1.26B |
| Gross profit | $1.12B | $1.7B | $1.65B | $1.53B | $1.55B |
| Research and development expenses | $144.8M | $161.7M | $154.4M | $153.8M | $130.8M |
| Selling, general and administrative expenses | $720.2M | $995.3M | $929.9M | $863.8M | $860.1M |
| Other expenses | $0.00 | $394.7M | $56.4M | $13.8M | -$-69.42M |
| Operating expenses | $865M | $1.55B | $1.14B | $1.03B | $921.5M |
| Cost and expenses | $1.74B | $2.9B | $2.47B | $2.29B | $2.18B |
| Interest income | $6.4M | $8.01M | $12.8M | $910K | $1.33M |
| Interest expense | $100.2M | $83.5M | $85.1M | $54.3M | $57M |
| Depreciation and amortization | $177.7M | $274.6M | $242.1M | $230.6M | $237.4M |
| Ebitda | $302.5M | $433.6M | $761.2M | $730.8M | $853.8M |
| Operating income | $255.8M | $151M | $506.3M | $499.7M | $628.1M |
| Total other income/expenses, net | -$-231.25M | -$-75.53M | -$-72.3M | -$-53.81M | -$-68.63M |
| Income before tax | $24.6M | $75.5M | $434M | $445.9M | $559.5M |
| Income tax expense | -$-33.98M | $5.32M | $76.4M | $83M | $74.4M |
| Net income | -$-905.64M | $69.7M | $356.3M | $363.1M | $485.4M |
| Weighted average shares outstanding | $44.6M | $46.8M | $47M | $46.9M | $46.8M |
| Weighted average diluted shares outstanding | $44.7M | $47.1M | $47.3M | $47.3M | $47.4M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $393.3M | $306.2M | $222.9M | $292M | $445.1M |
| Net receivables | $345.6M | $459.5M | $443.5M | $408.8M | $383.6M |
| Inventory | $404.4M | $600.1M | $626.2M | $578.5M | $477.6M |
| Total current assets | $1.94B | $1.47B | $1.41B | $1.41B | $1.43B |
| Property, plant and equipment, net | $590.1M | $611.8M | $603.4M | $578.4M | $573.4M |
| Goodwill and intangible assets | $3.83B | $4.9B | $5.42B | $4.84B | $4.79B |
| Long-term investments | $11.2M | $0.00 | $0.00 | $11.9M | $0.00 |
| Total non-current assets | $5.01B | $5.63B | $6.13B | $5.52B | $5.44B |
| Total assets | $6.95B | $7.1B | $7.53B | $6.93B | $6.87B |
| Accounts payable | $130.2M | $141M | $132.3M | $126.8M | $118.2M |
| Short-term debt | $100M | $100M | $87.5M | $87.5M | $110M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $762M | $649.4M | $606.8M | $581.5M | $680.1M |
| Long-term debt | $2.63B | $1.66B | $1.84B | $1.74B | $1.86B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $3.06B | $2.17B | $2.48B | $2.32B | $2.44B |
| Capital lease obligations | $84.2M | $99.2M | $111.3M | $120.4M | $116M |
| Total liabilities | $3.82B | $2.82B | $3.09B | $2.91B | $3.12B |
| Common stock | $48.2M | $48.1M | $48.1M | $48M | $47.9M |
| Retained earnings | $3.15B | $4.12B | $4.11B | $3.82B | $3.52B |
| Accumulated other comprehensive income (loss) | -$-239.47M | -$-316.67M | -$-314.4M | -$-403.52M | -$-346.96M |
| Total equity | $3.12B | $4.28B | $4.44B | $4.02B | $3.75B |
| Total investments | $11.2M | $16M | $0.00 | $11.9M | $0.00 |
| Total debt | $2.73B | $1.76B | $1.93B | $1.83B | $1.97B |
| Net debt | $2.33B | $1.46B | $1.7B | $1.54B | $1.52B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $58.5M | $69.7M | $356.3M | $363.1M | $485.4M |
| Depreciation and amortization | $177.7M | $274.6M | $242.1M | $230.6M | $237.4M |
| Stock-based compensation | $0.00 | $31.4M | $31.5M | $27.2M | $22.9M |
| Change in working capital | -$-81.09M | -$-1.82M | -$-111.77M | -$-239.96M | $127.3M |
| Accounts receivable | -$-85.53M | -$-27.95M | -$-15.76M | -$-38.46M | -$-600K |
| Inventory | $84M | $1.72M | -$-41.07M | -$-110.69M | -$-11.14M |
| Accounts payable | -$-8.28M | $9.66M | -$-31.26M | -$-24.79M | $94M |
| Net cash provided by operating activities | $340.7M | $635.7M | $510.6M | $342.1M | $651.4M |
| Investments in property, plant and equipment | -$-95.24M | -$-126.43M | -$-91.44M | -$-79.19M | -$-71.62M |
| Acquisitions, net | -$-825.14M | -$-120K | -$-588.92M | -$-186M | $220.3M |
| Net cash used for investing activities | -$-849.19M | -$-99.36M | -$-621.23M | -$-257.94M | $156.7M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $4.31M | $11.1M |
| Common stock repurchased | -$-300M | -$-200M | $0.00 | -$-4.31M | $0.00 |
| Dividends paid | -$-60.27M | -$-63.54M | -$-63.9M | -$-63.79M | -$-63.65M |
| Net cash used for financing activities | $611.5M | -$-421.93M | $38.5M | -$-217.51M | -$-715.82M |
| Net change in cash | $73.7M | $104.8M | -$-69.19M | -$-153.05M | $69.2M |
| Cash at end of period | $378.6M | $327.7M | $222.9M | $292M | $445.1M |
| Operating cash flow | $340.7M | $635.7M | $510.6M | $342.1M | $651.4M |
| Capital expenditure | -$-95.24M | -$-126.43M | -$-91.44M | -$-79.19M | -$-71.62M |
| Free cash flow | $245.4M | $509.3M | $419.2M | $263M | $579.8M |
Line items
Line items
Line items
About Teleflex Incorporated
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.
- CEO
- Jason Weidman
- Employees
- 15.5K
- Beta
- 0.82
Included in
Explore
Frequently asked questions
What is the intrinsic value of Teleflex Incorporated (TFX)?
Teleflex Incorporated (TFX) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is TFX undervalued?
TFX trades at a price of $161.58 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.